Compare · A vs ASTC
A vs ASTC
Side-by-side comparison of Agilent Technologies Inc. (A) and Astrotech Corporation (DE) (ASTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and ASTC operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $37.13B, about 2390.8x ASTC ($15.5M).
- Over the past year, A is up 15.3% and ASTC is up 42.0% - ASTC leads by 26.6 points.
- A has been more active in the news (9 items in the past 4 weeks vs 3 for ASTC).
- A has more recent analyst coverage (25 ratings vs 0 for ASTC).
- Company
- Agilent Technologies Inc.
- Astrotech Corporation (DE)
- Price
- $131.43-3.42%
- $7.85+4.88%
- Market cap
- $37.13B
- $15.5M
- 1M return
- +2.39%
- -50.03%
- 1Y return
- +15.31%
- +41.95%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- News (4w)
- 9
- 3
- Recent ratings
- 25
- 0
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Astrotech Corporation (DE)
Astrotech Corporation operates as a science and technology development and commercialization company worldwide. It operates through three segments, Astrotech Technologies, Inc. (ATI), 1st Detect Corporation (1st Detect), and AgLAB Inc (AgLAB). The ATI segment owns and licenses the AMS Technology, the platform mass spectrometry technology. The 1st Detect segment manufactures explosives and narcotics trace detectors for use at airports, secured facilities, and borders. This segment provides TRACER 1000, a mass spectrometer based explosives trace detector to replace the explosives trace detectors used at airports, cargo and secured facilities, and borders. The AgLAB segment develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. It also develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 is based in Austin, Texas.
Latest A
- Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
- Jefferies resumed coverage on Agilent with a new price target
- Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
- Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
- Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.21% to 14,108 units (SEC Form 4)
- Bernstein resumed coverage on Agilent with a new price target
- Agilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies
- Agilent Completes Acquisition of Biocare Medical
- Piper Sandler initiated coverage on Agilent with a new price target
Latest ASTC
- SEC Form EFFECT filed by Astrotech Corporation (DE)
- Astrotech Corporation Submits Proposal to NASA's Commercial Lunar Payload Services 2 Program
- SEC Form S-3 filed by Astrotech Corporation (DE)
- Astrotech Corporation (DE) filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Astrotech Board Approves Potential Sale Process of 1st Detect and TRACER 1000, the Only Field-Deployed Mass Spectrometry ETD, as the Company Focuses on Its Initiative in Space
- Astrotech Corporation's 1st Detect TRACER 1000 Receives ECAC Certification for Wand Swabbing
- Astrotech Corporation (DE) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by Astrotech Corporation (DE)
- Astrotech Corporation Board of Directors Approves Strategic Lunar Resource and Infrastructure Initiative to Advance Future Moon-Based Quantum Computing Manufacturing
- Director Wilkinson Tom was granted 6,006 shares, increasing direct ownership by 25% to 29,868 units (SEC Form 4)